AVEO presents tivozanib Phase 2 study results at ESMO Congress AVEO Pharmaceuticals.

‘The efficacy and tolerability demonstrated by these Stage 2 data further highlight the role that tivozanib may play in the treating patients with kidney tumor and other significant cancers, as a single agent or in conjunction with other therapies. I am very happy to be participating in the Phase 3 TIVO-1 trial, and look forward to learning more about this much-required potential treatment option as those data become available.’ These data were offered today by Dmitry A. Nosov, M.D., Ph.D., senior scientific researcher at the Blokhin Oncology Research Center, Moscow, Russian Federation, within an oral presentation titled, ‘Phase 2 Randomized Discontinuation Trial of Tivozanib in Patients With Renal Cell Carcinoma : Results in Individuals Randomized to Tivozanib vs..

Allina Hospitals, NextGen Health care enter partnership to foster better patient care coordination NextGen Healthcare Details Systems, Inc., a wholly possessed subsidiary of Quality Systems, Inc. And a respected provider of healthcare details connectivity and systems solutions, today announced that it has partnered with Allina Hospitals & Treatment centers to foster better individual care coordination among doctor practices of most sizes in Minnesota and Western Wisconsin. Related StoriesCancer analysis improvements in England: an interview with Lucy Elliss-BrookesSurgical startup seeks funding to build digital reality teaching libraryApplying a high restaurant model to health care communications: an interview with Brandi Robinson, Sanofi By enabling a broad network of connectivity, Allina hopes to improve care, efficiency and convenience for all sufferers while helping our physicians meet Meaningful Use standards and lower the total cost of treatment, said Robert Wieland, MD, Executive Vice President, Ambulatory Care, for Allina Hospitals & Clinics.